Suzetrigine Added to Multimodal Analgesia for Women Undergoing Minimally Invasive Hysterectomy

Phase 4 Not yet recruiting 123 enrolled Duke University Vertex Pharmaceuticals Incorporated · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess the analgesic efficacy of suzetrigine as part of a multimodal analgesic regimen in women undergoing laparoscopic or robotic hysterectomy. Outcomes will be compared with matched historical controls receiving the current ERAS regimen without suzetrigine.

Timeline

Start: 2026-11
Primary completion: 2028-01
Completion: 2028-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Suzetrigine	Small molecule	50 mg	Oral

Indications

No indication recorded.